Investigational Drug Details
| Drug ID: | D110 |
| Drug Name: | Sorafenib |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00398 |
| DrugBank Description: | Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway. |
| PubChem ID: | 216239 |
| CasNo: | 284461-73-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 |
| Structure: |
|
| InChiKey: | MLDQJTXFUGDVEO-UHFFFAOYSA-N |
| Molecular Weight: | 464.825 |
| DrugBank Targets: | Serine/threonine-protein kinase B-raf; RAF proto-oncogene serine/threonine-protein kinase; Vascular endothelial growth factor receptor 3; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 1; Receptor-type tyrosine-protein kinase FLT3; Platelet-derived growth factor receptor beta; Mast/stem cell growth factor receptor Kit; Fibroblast growth factor receptor 1; Proto-oncogene tyrosine-protein kinase receptor Ret |
| DrugBank MoA: | Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. Sorafenib is unique in targeting the Raf/Mek/Erk pathway. By inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited. |
| DrugBank Pharmacology: | No large changes in QTc interval were observed. After one 28-day treatment cycle, the largest mean QTc interval change of 8.5 ms (upper bound of two-sided 90% confidence interval, 13.3 ms) was observed at 6 hours post-dose on day 1 of cycle 2. |
| DrugBank Indication: | Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|